Response to “Phase IV head-to-head randomised controlled trial comparing ingenol mebutate 0.015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp” – reply from authors

Abstract

We thank Drs Malvehy and Puig for their comments on the article; our responses follow. Drs Malvehy and Puig correctly note that the primary endpoint is complete clearance at the end of the first treatment course. Here, the rates are 34.5% for IngMeb and 23.5% for DS. It is not clear why Malvehy and Puig believe that a comparison at the same time point would be better.

This article is protected by copyright. All rights reserved.